文献速递消化、代谢与肾脏急症中毒与环境急症

氟哌啶醇、氟哌利多与昂丹司琼治疗急诊大麻素剧吐综合征的比较效果

Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department
RSS 订阅 · Academic Emergency Medicine · 2026-11-05
一句话结论多中心回顾性队列显示,疑似大麻素剧吐综合征成人中,氟哌啶醇和氟哌利多较昂丹司琼与更低的72小时急诊复诊率相关。

该多中心回顾性队列研究利用TriNetX研究网络2014至2024年数据,纳入因呕吐相关和 cannabis 相关ICD-10诊断就诊急诊并接受氟哌啶醇、氟哌利多或昂丹司琼的成人,排除其他呕吐原因或主要混杂疾病。经倾向评分匹配后,氟哌啶醇组72小时急诊复诊率8.2%低于昂丹司琼组15.1%(OR 0.50,95%CI 0.41–0.62),氟哌利多组7.4%低于昂丹司琼组14.0%(OR 0.49,95%CI 0.32–0.76),氟哌利多与氟哌啶醇无显著差异(7.5% vs 9.8%;OR 0.75,95%CI 0.47–1.20)。多变量模型中氟哌啶醇(HR 0.62,95%CI 0.49–0.79)和氟哌利多(HR 0.68,95%CI 0.56–0.83)与较低复诊风险独立相关,昂丹司琼则无。各组编码不良事件均罕见。

要点

  • 倾向评分匹配后,氟哌啶醇组72小时急诊复诊率8.2%,低于昂丹司琼组15.1%(OR 0.50,95%CI 0.41–0.62)。
  • 氟哌利多组72小时急诊复诊率7.4%,低于昂丹司琼组14.0%(OR 0.49,95%CI 0.32–0.76)。
  • 氟哌利多与氟哌啶醇72小时急诊复诊率无显著差异(7.5% vs 9.8%;OR 0.75,95%CI 0.47–1.20)。
  • 多变量模型中氟哌啶醇(HR 0.62,95%CI 0.49–0.79)和氟哌利多(HR 0.68,95%CI 0.56–0.83)与较低复诊风险独立相关,昂丹司琼无此关联。
  • 各组编码不良事件均罕见。

适用人群与场景

  • 因呕吐相关和 cannabis 相关ICD-10诊断就诊急诊的成人,且就诊期间接受氟哌啶醇、氟哌利多或昂丹司琼。
  • 排除其他呕吐原因或主要混杂疾病的患者。

研究设计与关键结果

  • 研究类型为多中心回顾性队列研究,使用TriNetX研究网络2014至2024年数据,纳入符合疑似大麻素剧吐综合征表型的成人。
  • 主要终点为72小时急诊复诊:氟哌啶醇组8.2% vs 昂丹司琼组15.1%(OR 0.50,95%CI 0.41–0.62;p<0.0001)。
  • 氟哌利多组72小时急诊复诊率7.4% vs 昂丹司琼组14.0%(OR 0.49,95%CI 0.32–0.76;p=0.0014)。
  • 氟哌利多与氟哌啶醇72小时急诊复诊率无显著差异(7.5% vs 9.8%;OR 0.75,95%CI 0.47–1.20;p=0.23)。
  • 多变量Cox比例风险模型:氟哌啶醇HR 0.62(95%CI 0.49–0.79),氟哌利多HR 0.68(95%CI 0.56–0.83),均与较低复诊风险独立相关;昂丹司琼无此关联。
  • 各组编码不良事件均罕见。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在符合疑似大麻素剧吐综合征表型的成人急诊患者中,氟哌啶醇和氟哌利多较昂丹司琼与更低的72小时急诊复诊率相关。
  • 作者认为这些发现支持开展前瞻性研究评估氟哌啶醇和氟哌利多用于大麻素剧吐综合征的急诊管理,包括最佳剂量、给药途径、用药顺序、出院治疗和安全监测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

ABSTRACT BackgroundCannabinoid hyperemesis syndrome (CHS) is an increasingly frequent emergency department (ED) presentation. Although ondansetron is commonly used, emerging evidence suggests haloperidol and droperidol may provide more effective symptom control. Robust comparative effectiveness data, particularly regarding short-term ED recidivism, remain limited.MethodsWe conducted a multicenter retrospective cohort study using the TriNetX Research Network from 2014 to 2024. Adults presenting to the ED with vomiting-related and cannabis-related ICD-10 diagnoses who received haloperidol, droperidol, or ondansetron during the index encounter were included. Patients with alternative causes of vomiting or major confounding conditions were excluded. Propensity-score matching was performed for three pairwise comparisons: haloperidol versus ondansetron, droperidol versus ondansetron, and droperidol versus haloperidol. The primary outcome was 72-h ED recidivism. Secondary outcomes included 72-h hospital admission, 7-day ED recidivism, and coded adverse events. Multivariable Cox proportional hazards modeling evaluated independent predictors of 72-h ED recidivism.ResultsAfter matching, haloperidol was associated with lower 72-h ED recidivism compared with ondansetron (8.2% vs. 15.1%; OR 0.50, 95% CI 0.41–0.62; p < 0.0001). Droperidol was also associated with lower 72-h ED recidivism compared with ondansetron (7.4% vs. 14.0%; OR 0.49, 95% CI 0.32–0.76; p = 0.0014). Droperidol and haloperidol did not differ significantly in 72-h ED recidivism (7.5% vs. 9.8%; OR 0.75, 95% CI 0.47–1.20; p = 0.23). In the multivariable model, haloperidol (HR 0.62, 95% CI 0.49–0.79) and droperidol (HR 0.68, 95% CI 0.56–0.83) were independently associated with lower return risk, whereas ondansetron was not. Coded adverse events were rare across all groups.ConclusionsIn this large multicenter cohort, haloperidol and droperidol were associated with lower short-term ED recidivism than ondansetron among adults meeting a suspected CHS phenotype. These findings support prospective studies evaluating haloperidol and droperidol for ED management of CHS, including optimal dosing, route, medication sequencing, discharge treatment, and safety monitoring.

来源:Academic Emergency Medicine,查看原文。版权归原作者所有。

参考来源

  1. Academic Emergency Medicine:Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。